Alunbrig 90mg

Alunbrig 90mg  Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with brigatinib; monitor for new or worsening respiratory symptoms (eg, dyspnea, cough), particularly during the first week of initiating.Alunbrig 90mg

• Dose-related hypertension reported; control BP prior to treatment; monitor BP after 2 weeks and at least monthly thereafter.
• Bradycardia (HR <50 bpm) reported; monitor HR and BP; monitor more frequently if concomitant use of drugs known to cause bradycardia cannot be avoided.
• May cause visual disturbances; advise patients to report any visual symptoms.
• Increased CPK reported; advise patients to report any unexplained muscle pain, tenderness, or weakness; monitor CPK during treatment.Brand Name : Briganix Alunbrig 90mg
  Composition : Brigatinib 90mg
  Manufactured by : Beacon Pharmaceuticals
  Form : Alunbrig 90mgAlunbrig 90mg (0 TabletsMore Information on Tablets | 98.4 Pharmacy Online

  98.4 Pharmacy advice for Briganix 90mg 30 Tablets

  Packing : Pack of 30 Tablets

• Serum pancreatic enzyme elevation reported; monitor lipase and amylase during treatment.
• May cause new or worsening hyperglycemia; assess fasting serum glucose before initiating drug and periodically thereafter; initiate or optimize antihyperglycemic medications as needed.

• More Information on Briganix 90mg 30 Tablets | 98.4 Pharmacy Online

  98.4 Pharmacy advice for Alunbrig 90mg

  • Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with brigatinib; monitor for new or worsening respiratory symptoms (eg, dyspnea, cough), particularly during the first week of initiating.
  • Dose-related hypertension reported; control BP prior to treatment; monitor BP after 2 weeks and at least monthly thereafter.
  • Bradycardia (HR <50 bpm) reported; monitor HR and BP; monitor more frequently if concomitant use of drugs known to cause bradycardia cannot be avoided.
  • May cause visual disturbances; advise patients to report any visual symptoms.
  • Increased CPK reported; advise patients to report any unexplained muscle pain, tenderness, or weakness; monitor CPK during treatment.
  • Serum pancreatic enzyme elevation reported; monitor lipase and amylase during treatment.
  • May cause new or worsening hyperglycemia; assess fasting serum glucose before initiating drug and periodically thereafter; initiate or optimize antihyperglycemic medications as needed.  http://premierhorsemed.com